Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Rapid Micro Biosystems downgraded to Neutral from Overweight at JPMorgan » 07:21
08/16/22
08/16
07:21
08/16/22
07:21
RPID

Rapid Micro Biosystems

$3.85 /

-0.15 (-3.75%)

JPMorgan analyst Rachel…

JPMorgan analyst Rachel Vatnsdal downgraded Rapid Micro Biosystems to Neutral from Overweight and withdrew her prior $10 price target on the shares after the company reported a disappointing set of Q2 results and FY22 outlook last Friday. Rapid also announced that the company would be initiating a review of strategic alternatives and implement an organizational restructuring plan that involves the departure of the CCO and a 20% reduction to the company's non-commercial workforce, Vatnsdal noted. The Q2 results and commentary show that recent lackluster performance is less transitory and pandemic-related than she'd thought and "more structural in nature," the analyst tells investors.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$3.85 /

-0.15 (-3.75%)

RPID Rapid Micro Biosystems
$3.85 /

-0.15 (-3.75%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$3.85 /

-0.15 (-3.75%)

RPID Rapid Micro Biosystems
$3.85 /

-0.15 (-3.75%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
08/12/22
08/12
08:59
08/12/22
08:59
UBX

Unity Biotechnology

$0.85 /

-0.1199 (-12.36%)

, APLT

Applied Therapeutics

$1.31 /

+0.09 (+7.38%)

, RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

, AIRS

AirSculpt Technologies

$8.85 /

-0.45 (-4.84%)

, PAYO

Payoneer Global

$5.68 /

+0.045 (+0.80%)

, TOST

Toast

$18.12 /

-0.33 (-1.79%)

, RIVN

Rivian Automotive

$38.91 /

+1.475 (+3.94%)

, LPTX

Leap Therapeutics

$1.32 /

+0.15 (+12.82%)

, PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

, SPB

Spectrum Brands

$70.37 /

+0.75 (+1.08%)

, CODX

Co-Diagnostics

$6.44 /

-0.195 (-2.94%)

, ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

, LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

, ELF

e.l.f. Beauty

$36.44 /

-0.02 (-0.05%)

Check out this morning's…

ShowHide Related Items >><<
UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

06/16/22 Morgan Stanley
AirSculpt downgraded to Equal Weight from Overweight at Morgan Stanley
02/09/22 Piper Sandler
Piper Sandler bullish into AirSculpt Technologies Q4 results
01/25/22 Piper Sandler
AirSculpt Technologies transferred with Overweight at Piper Sandler
12/21/21 Piper Sandler
AirSculpt should could double from current levels, says Piper Sandler
PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

07/14/22 Goldman Sachs
Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
05/13/22 Northland
Payoneer Global price target lowered to $9 from $14 at Northland
05/13/22 Citi
Payoneer Global price target raised to $7.50 from $6.50 at Citi
03/04/22 Needham
Payoneer Global price target lowered to $7 from $13 at Needham
TOST Toast
$18.12 /

-0.33 (-1.79%)

08/12/22 Needham
Toast price target raised to $27 from $21 at Needham
08/12/22 KeyBanc
Toast price target raised to $25 from $18 at KeyBanc
05/17/22 Mizuho
Toast price target lowered to $18 from $19 at Mizuho
05/13/22 Needham
Toast price target lowered to $21 from $38 at Needham
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

08/12/22 DA Davidson
Rivian Automotive price target raised to $27 from $24 at DA Davidson
08/12/22 Morgan Stanley
Rivian Automotive's liqudity can last through most of FY23, says Morgan Stanley
08/12/22 Mizuho
Rivian Automotive price target lowered to $65 from $70 at Mizuho
07/18/22 Deutsche Bank
Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank
LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

06/06/22 Piper Sandler
Piper says Leap's DKN-01 combo showed 'interesting early signal of activity'
05/27/22 Piper Sandler
Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
01/23/22 Piper Sandler
Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

07/18/22 Oppenheimer
Spectrum Brands price target lowered to $95 from $125 at Oppenheimer
07/18/22 UBS
Spectrum Brands price target lowered to $109 from $119 at UBS
07/18/22 Wells Fargo
Spectrum Brands price target lowered to $100 from $122 at Wells Fargo
07/13/22 Raymond James
Spectrum Brands initiated with a Market Perform at Raymond James
CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

08/12/22 Sidoti
Co-Diagnostics downgraded to Neutral from Buy at Sidoti
05/16/22 H.C. Wainwright
Co-Diagnostics price target lowered to $12 from $15 at H.C. Wainwright
12/29/21 Sidoti
Sidoti starts Co-Diagnostics at Buy, sees opportunities opened by COVID-19 test
12/29/21 Sidoti
Co-Diagnostics initiated with a Buy at Sidoti
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/12/22 Piper Sandler
Piper a buyer of Illumina weakness ahead of Genomics Forum
08/12/22 Canaccord
Illumina price target lowered to $380 from $450 at Canaccord
08/12/22 Stifel
Illumina price target lowered to $300 from $480 at Stifel
08/12/22 Citi
Illumina price target lowered to $200 from $220 at Citi
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

08/12/22 Canaccord
CS Disco downgraded to Hold at Canaccord as estimates get reset
08/12/22 Stifel
CS Disco price target lowered to $30 from $40 at Stifel
08/12/22 BofA
CS Disco downgraded to Neutral from Buy at BofA
08/12/22 Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform at Cowen on valuation
08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform from Outperform at Cowen
08/04/22 Truist
e.l.f. Beauty price target raised to $40 from $35 at Truist
07/21/22 JPMorgan
e.l.f. Beauty price target raised to $35 from $30 at JPMorgan
UBX Unity Biotechnology
$0.85 /

-0.1199 (-12.36%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SPB Spectrum Brands
$70.37 /

+0.75 (+1.08%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

  • 23
    Jun
  • 10
    Nov
  • 29
    Oct
  • 22
    Sep
  • 22
    Sep
  • 15
    Sep
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

AIRS AirSculpt Technologies
$8.85 /

-0.45 (-4.84%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

Hot Stocks
Rapid Micro Biosystems adopts stockholder rights plan » 07:08
08/12/22
08/12
07:08
08/12/22
07:08
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Rapid Micro Biosystems also announced that its Board has unanimously adopted a limited-duration stockholder rights plan. The Rights Plan is intended to enable all shareholders to realize the full value of their investment in the Company, and to protect the Company and its shareholders from efforts to obtain control of the Company that the Board determines are not in the best interests of the Company and its shareholders. It will also provide the Board with the appropriate time and flexibility to conduct its review of strategic alternatives and pursue the best course of action for all shareholders. The Rights Plan does not preclude the Board from engaging with parties or considering an offer that it believes recognizes the full value of the Company and is in the best interests of Rapid Micro Biosystems and its shareholders. The Rights Plan is similar to shareholder rights plans adopted by other publicly traded companies. The rights will become exercisable if an entity, person or group acquires beneficial ownership of 15% or more of the Company's outstanding Class A common stock. In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder to receive shares of common stock of the Company having a market value equal to two times the Exercise Price. Under the Rights Plan, any person, entity or group which currently owns more than the triggering percentage may continue to own its shares of common stock but may not acquire any additional shares of Class A common stock without triggering the Rights Plan. The Rights Plan does not contain any dead-hand, slow-hand, no-hand or similar feature that would limit the ability of a future Board of Directors to redeem the rights. The Rights Plan will automatically expire on the day after the Company's 2023 Annual Meeting of Stockholders, unless approved by the Company's stockholders at the 2023 Annual Meeting, in which case it will expire in one year, on August 11, 2023.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Hot Stocks
Rapid Micro Biosystems announces review of strategic alternatives » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Rapid Micro Biosystems announced that its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value. The Board has retained Morgan Stanley & Co. LLC as its financial advisor and Goodwin Procter as its legal advisor to assist in its review of a wide range of options including, among other things a sale, merger or other strategic transaction. In addition, the Company announced that its Board of Directors has unanimously rejected an unsolicited non-binding proposal from Kennedy Lewis Investment Management to acquire all of the outstanding shares of the Company for $5.00 per share in cash. Following a comprehensive review, in consultation with its financial and legal advisors, the Board determined that the proposal is inadequate and is not in the best interest of the Company or its shareholders. "The Company is taking decisive action to right-size its cost structure to allow continued focus on enhanced commercial execution and key product development initiatives while also managing its significant cash balance and long cash runway," said Jeffrey Schwartz, Chairperson of the Board of Directors. "As we seek to accelerate this work and best position our business for the future, the Board believes now is the right time to explore alternatives to determine the best path to maximize shareholder value. The Board is committed to exploring a range of alternatives, while simultaneously prioritizing and advancing important initiatives within the business, that we believe will enhance value for our shareholders."

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Hot Stocks
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

In addition, the Company…

In addition, the Company announced that its Board of Directors has unanimously rejected an unsolicited non-binding proposal from Kennedy Lewis Investment Management to acquire all of the outstanding shares of the Company for $5.00 per share in cash. Following a comprehensive review, in consultation with its financial and legal advisors, the Board determined that the proposal is inadequate and is not in the best interest of the Company or its shareholders.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Hot Stocks
Rapid Micro Biosystems CCO Andy Keys departs » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

In connection with the…

In connection with the organizational restructuring plan, the Company also announced that Andy Keys is leaving his role as Chief Commercial Officer effective immediately and Mr. Spignesi is assuming commercial leadership responsibilities.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Hot Stocks
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

The Company is…

The Company is implementing an organizational restructuring plan to right-size its cost structure based on its lowered 2022 outlook. The Company will continue to invest in key growth initiatives including enhancing commercial execution and key product development programs that are expected to drive future revenue growth. The plan involves an approximately 20% reduction in the Company's workforce, which is largely focused on non-commercial functions. The Company expects the organizational restructuring plan to result in approximately $8.0 - $9.0 million in annualized cost savings by the first quarter 2023. It expects to incur restructuring charges of approximately $1.5 million to be recognized in the third quarter of fiscal year 2022.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Earnings
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M » 07:03
08/12/22
08/12
07:03
08/12/22
07:03
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Consensus $28.01M. The…

Consensus $28.01M. The Company is updating its prior full year 2022 revenue outlook to at least $17.0 million. This assumes that the Company will place between three and five systems in the second half of the year, with most or all of those placements made in the fourth quarter. The Company's lowered guidance reflects expectations for fewer systems placements in fiscal year 2022 as it continues to ramp its commercial team and optimize its commercial execution as well as macro-economic uncertainty that is expected to persist through the second half of the year.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Earnings
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year » 07:02
08/12/22
08/12
07:02
08/12/22
07:02
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Reports Q2 revenue…

Reports Q2 revenue $3.86M, consensus $4.57M. "While we placed two systems in the second quarter in line with our guidance, revenue was slightly below our expectations mainly due to slower-than-expected progress on a few system validations in the second half of the quarter as well as third-party logistics delays in the final days of the quarter that pushed revenue from several significant consumable shipments into the third quarter. We expect substantially all of the impacted revenues to be recognized in the third quarter. Excluding the impact of the delays in consumables, recurring revenue grew over 40% compared to the second quarter of last year, evidencing the continued strength of our business model and customer value proposition," said Robert Spignesi, President and CEO. "As access to customer sites and in-person engagement continued to improve gradually as we moved through the second quarter and into the third quarter, we have learned more about the challenges the pandemic created for our customers in advancing capital purchasing decisions and for us in accurately assessing the timing of sales opportunities. We have also identified opportunities to improve aspects of our sales process and sales team training. At the same time, macroeconomic uncertainty is impacting the timing of some customer purchase decisions. As a result of our post-quarter analysis, we now anticipate fewer system placements for the full year and, accordingly, we are lowering our 2022 revenue outlook. We are taking decisive actions to enhance our commercial execution and right-size our cost structure to maintain our ability to invest in key growth initiatives while also managing our significant cash balance and long cash runway. We are confident these actions will better position us to capitalize on the large and growing market opportunity for our Growth Direct System."

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

Over a quarter ago
Hot Stocks
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis » 14:37
06/30/22
06/30
14:37
06/30/22
14:37
RPID

Rapid Micro Biosystems

$4.36 /

+1.19 (+37.54%)

Rapid Micro Biosystems…

Rapid Micro Biosystems confirmed that it has received an unsolicited, non-binding proposal from Kennedy Lewis Investment Management LLC to acquire all of the outstanding shares of the Company for $5.00 per share in cash. Consistent with its fiduciary duties and in consultation with its independent advisors, the Rapid Micro Biosystems Board of Directors will carefully review the unsolicited proposal to determine the course of action that it believes is in the best interest of the Company and all Rapid Micro Biosystems shareholders. Rapid Micro Biosystems shareholders do not need to take any action at this time.

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.36 /

+1.19 (+37.54%)

RPID Rapid Micro Biosystems
$4.36 /

+1.19 (+37.54%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
08/09/21 Cowen
Rapid Micro Biosystems initiated with an Outperform at Cowen
08/09/21 JPMorgan
JPMorgan starts Rapid Micro Biosystems at Overweight with $30 price target
08/09/21 Stifel
Rapid Micro Biosystems initiated with a Buy at Stifel
RPID Rapid Micro Biosystems
$4.36 /

+1.19 (+37.54%)

  • 15
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.